A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load

BACKGROUND: Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to determine optimal dose and expand availability of treatment. METHODS: This Phase 3 portion of the BLAZE-1 trial characterized the effect of bamlanivimab wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Dougan, Michael, Azizad, Masoud, Mocherla, Bharat, Gottlieb, Robert L, Chen, Peter, Hebert, Corey, Perry, Russell, Boscia, Joseph, Heller, Barry, Morris, Jason, Crystal, Chad, Igbinadolor, Awawu, Huhn, Gregory, Cardona, Jose, Shawa, Imad, Kumar, Princy, Blomkalns, Andra, Adams, Andrew C, Van Naarden, Jacob, Custer, Kenneth L, Knorr, Jack, Oakley, Gerard, Schade, Andrew E, Holzer, Timothy R, Ebert, Philip J, Higgs, Richard E, Sabo, Janelle, Patel, Dipak R, Dabora, Matan C, Williams, Mark, Klekotka, Paul, Shen, Lei, Skovronsky, Daniel M, Nirula, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402688/
https://www.ncbi.nlm.nih.gov/pubmed/34718468
http://dx.doi.org/10.1093/cid/ciab912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402688/
https://www.ncbi.nlm.nih.gov/pubmed/34718468
http://dx.doi.org/10.1093/cid/ciab912

Ejemplares similares